The MexXY-OprM multidrug efflux pump (EP) in aminoglycosides resistant Pseudomonas aeruginosa is one of the major resistance mechanisms, which is often overexpressed in strains isolated from pulmonary chronic disease such as cystic fibrosis.[1-3] In this research, we focused on the design of potential efflux pumps inhibitors, targeting MexY, the inner membrane component, in an allosteric site. Berberine[4] has been considered as lead molecule since we previously demonstrated its effectiveness in targeting MexY in laboratory reference strains.[5,6] Since this protein is often present in polymorphic variants in clinical strains, we sequenced and modeled all the mutated forms and we synthesized and evaluated by computational techniques, some berberine derivatives carrying an aromatic functionalization in its 13-C ring position. These compounds were tested in vitro against clinical P. aeruginosa strains for antimicrobial and antibiofilm activity. In conclusion, the results demonstrated the importance of the aromatic moiety functionalization in exerting the EP inhibitory activity in synergy with the aminoglycoside tobramycin. More, we found that aminoacidic composition of MexY in different strains must be considered for predicting potential binding site and affects the different activity of berberine derivatives. Finally, the antibiofilm effect of these new EPIs is promising, particularly for o-CH3-berberine derivative.Unveiling Strategies to Combat Drug Resistance: Our study delves into the battle against drug resistance in aminoglycosides resistant Pseudomonas aeruginosa, focusing on the MexXY-OprM multidrug efflux pump system. We explore the design of novel efflux pump inhibitors, targeting MexY at an identified allosteric site (ALP). Lead compound Berberine and its derivatives show promise in inhibiting the pump and reducing biofilm production, offering new avenues in the fight against chronic pulmonary diseases

Inhibition of polymorphic MexXY-OprM efflux system in Pseudomonas aeruginosa clinical isolates by Berberine derivatives / Giorgini, Giorgia; Di Gregorio, Alessandra; Mangiaterra, Gianmarco; Cedraro, Nicholas; Minnelli, Cristina; Sabbatini, Giulia; Mobbili, Giovanna; Simoni, Serena; Vignaroli, Carla; Galeazzi, Roberta. - In: CHEMMEDCHEM. - ISSN 1860-7187. - 19:5(2024). [10.1002/cmdc.202300568]

Inhibition of polymorphic MexXY-OprM efflux system in Pseudomonas aeruginosa clinical isolates by Berberine derivatives

Giorgini, Giorgia;Di Gregorio, Alessandra;Minnelli, Cristina;Sabbatini, Giulia;Mobbili, Giovanna;Simoni, Serena;Vignaroli, Carla;Galeazzi, Roberta
2024-01-01

Abstract

The MexXY-OprM multidrug efflux pump (EP) in aminoglycosides resistant Pseudomonas aeruginosa is one of the major resistance mechanisms, which is often overexpressed in strains isolated from pulmonary chronic disease such as cystic fibrosis.[1-3] In this research, we focused on the design of potential efflux pumps inhibitors, targeting MexY, the inner membrane component, in an allosteric site. Berberine[4] has been considered as lead molecule since we previously demonstrated its effectiveness in targeting MexY in laboratory reference strains.[5,6] Since this protein is often present in polymorphic variants in clinical strains, we sequenced and modeled all the mutated forms and we synthesized and evaluated by computational techniques, some berberine derivatives carrying an aromatic functionalization in its 13-C ring position. These compounds were tested in vitro against clinical P. aeruginosa strains for antimicrobial and antibiofilm activity. In conclusion, the results demonstrated the importance of the aromatic moiety functionalization in exerting the EP inhibitory activity in synergy with the aminoglycoside tobramycin. More, we found that aminoacidic composition of MexY in different strains must be considered for predicting potential binding site and affects the different activity of berberine derivatives. Finally, the antibiofilm effect of these new EPIs is promising, particularly for o-CH3-berberine derivative.Unveiling Strategies to Combat Drug Resistance: Our study delves into the battle against drug resistance in aminoglycosides resistant Pseudomonas aeruginosa, focusing on the MexXY-OprM multidrug efflux pump system. We explore the design of novel efflux pump inhibitors, targeting MexY at an identified allosteric site (ALP). Lead compound Berberine and its derivatives show promise in inhibiting the pump and reducing biofilm production, offering new avenues in the fight against chronic pulmonary diseases
2024
File in questo prodotto:
File Dimensione Formato  
Chem_Med_Chem_Galeazzi_rev1_submission-final 22-12.pdf

Open Access dal 13/01/2025

Descrizione: This is the peer reviewed version of the following article: G. Giorgini, A. Di Gregorio, G. Mangiaterra, N. Cedraro, C. Minnelli, G. Sabbatini, G. Mobbili, S. Simoni, C. Vignaroli, R. Galeazzi, ChemMedChem 2024, 19, e202300568. https://doi.org/10.1002/cmdc.202300568, which has been published in final form at https://doi.org/10.1002/cmdc.202300568. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited
Tipologia: Documento in post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza d'uso: Licenza specifica dell’editore
Dimensione 2.65 MB
Formato Adobe PDF
2.65 MB Adobe PDF Visualizza/Apri
ChemMedChem - 2024 - Giorgini - Inhibition of polymorphic MexXY‐OprM efflux system in Pseudomonas aeruginosa clinical.pdf

Solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso: Tutti i diritti riservati
Dimensione 4.8 MB
Formato Adobe PDF
4.8 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/327172
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact